• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

Senolytic CAR-T Development Service targeting Age-related Metabolic Dysfunction

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Senolytic CAR-T Cells for Anti-aging

Senescent cells are one of the main causes of aging and age-related diseases. Senescent cells can accumulate in tissues and organs, contributing to the development of multiple diseases, including age-related metabolic dysfunction. CAR-T therapy has shown considerable success in treating certain types of cancer, and scientists are now looking to apply this same technique to senescent cells. Recently, researchers have focused their efforts on developing senolytic CAR-T cells to target age-related metabolic dysfunctions. By engineering these cells to target proteins present in senescent cells, it may be possible to use the patient's immune system to clear away these harmful, aging cells, essentially 'rejuvenating' the tissue. This innovative technique could have significant applications in treating age-related diseases and metabolic dysfunction, such as diabetes and obesity.

Senolytic CAR-T Cells Targeting uPAR

Urokinase plasminogen activator receptor (uPAR) is a protein that is often overexpressed on the surface of senescent cells. Therefore, uPAR is an ideal target for senolytic CAR-T cells. By engineering CAR-T cells to target uPAR, senescent cells can potentially be eliminated, alleviating symptoms of age-related metabolic dysfunction. Creative Biolabs offers a comprehensive CAR-T cell development service, specializing in creating senolytic CAR-T cells that specifically target uPAR. This innovative approach is designed to combat age-related metabolic dysfunction, opening new avenues for potential treatments and therapies.

Fig.1 Schematic illustration of the treatment of cancer and chronic diseases using uPAR CAR T cells.¹

At Creative Biolabs, we provide high-quality services in the design and development of CAR-T cells for anti-aging applications. We have focused on age-related metabolic dysfunction and other similar age diseases. Our team of experts utilizes state-of-the-art technology to develop effective, personalized CAR-T cells. We offer one-stop services to design and develop senolytic CAR-T cells specifically targeting uPAR and other aging-related targets. We provide full support throughout the development process, from initial design to final delivery, ensuring the high quality and effectiveness of the CAR-T cells. Please reach out to us for more details about our senolytic CAR-T development service.

Support Data

Data 1: The expression of uPAR protein in the liver, adipose tissue, skeletal muscle and pancreas.

Result: uPAR protein is upregulated in aging mice as tested by IHC.

Fig.2 IHC staining of mouse uPAR from young or old mice.²

Data 2: The therapeutic potential of uPAR CAR-T cells in aged mice

Result: uPAR CAR-T cells showed improvements in their glucose metabolism and exercise capacity.

Fig.3 Effect of uPAR CAR T cells in aged mice.²

References

1. Huang, et al.; "Step further towards targeted senolytic therapy: therapeutic potential of uPAR-CAR T cells for senescence-related diseases." Signal Transduction and Targeted Therapy 5.1 (2020): 155.
2. Amor, et al.; "Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction." Nature Aging (2024): 1-14.